Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Windtree Therapeutics, Inc. - Common Stock (NQ:WINT)

0.7762 +0.0462 (+6.33%)
Streaming Delayed Price Updated: 12:16 PM EDT, Jul 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Windtree Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Windtree Therapeutics Heart Failure Drug Candidate Improves Systolic Blood Pressure
Windtree Therapeutics reports positive results from its Phase 2b study of istaroxime in patients with early cardiogenic shock, showing significant improvements in systolic blood pressure and a... 
Via Benzinga
Why Intuitive Machines Shares Are Trading Higher By Around 41%; Here Are 20 Stocks Moving Premarket
Via Benzinga
What's Going On With Windtree Therapeutics Stock Wednesday?
Windtree Therapeutics shares are trading higher Wednesday after the company completed enrollment of its SEISMiC Extension Phase 2b study of istaroxime. 
Via Benzinga
WINT Stock Earnings: Windtree Therapeutics Reported Results for Q1 2024
Windtree Therapeutics just reported results for the first quarter of 2024. 
Via InvestorPlace
(WINT) - Analyzing Windtree Therapeutics's Short Interest
Via Benzinga
Why Is Windtree Therapeutics (WINT) Stock Up 116% Today?
Windtree Therapeutics stock is up on Friday with heavy trading of WINT shares following an update on its clinical trials. 
Via InvestorPlace
(WINT) - Analyzing Windtree Therapeutics's Short Interest
Via Benzinga
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Why Windtree Therapeutics (WINT) Stock Is Volatile Today
Windtree Therapeutics shares are trading lower by 8.6% during Monday's session. The company announced it entered a $1M private placement. 
Via Benzinga
S&P 500 Gains Over 1%; 3M Shares Jump After Q2 Results
Via Benzinga
Topics Stocks
Why Saia Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Crude Oil Down Over 2%; Bristol Myers Squibb Posts Upbeat Q2 Results
Via Benzinga
Dow Surges 550 Points; Headline PCE Price Index Falls To 2.5%
Via Benzinga
Topics Stocks
What's Going On With Windtree Therapeutics Stock?
Windtree Therapeutics shares are racing higher Friday after the company requested the withdrawal of its Registration Statement previously filed with the SEC. 
Via Benzinga
Topics Regulatory Compliance
Why Is DexCom (DXCM) Stock Down 38% Today?
DexCom stock is up on Friday as DXCM investors react to the company's latest earnings report and its lackluster 2024 guidance. 
Via InvestorPlace
Why Is BurgerFi International (BFI) Stock Up 71% Today?
BurgerFi International stock is up on Friday as investors in BFI react to it reaching a settlement agreement with Lion Point Capital, LP. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Pre-market stock movers are worth diving into this morning as we check out all of the hottest news investors need to know about on Friday! 
Via InvestorPlace
Why Ultra Clean Shares Are Trading Higher By 17%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
We're diving into the biggest pre-market stock movers that traders need to know about on Friday morning with all of the latest news! 
Via InvestorPlace
Why Windtree Therapeutics (WINT) Stock Is Getting Hammered
Windtree Therapeutics shares are trading lower by 30% during Thursday's session. The company announced it approved a 1-for-18 reverse stock split of its common stock. 
Via Benzinga
Why Las Vegas Sands Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
WINT Stock Earnings: Windtree Therapeutics Beats EPS for Q4 2023
WINT stock results show that Windtree Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Windtree Therapeutics – This Biotech Inks License Deal For Lead Candidate
Craig Fraser, CEO of Windtree Therapeutics, Inc. (NASDAQ: WINT), was recently interviewed by Benzinga. Windtree is advancing late-stage interventions for cardiovascular disorders to treat patients in... 
Via Benzinga
Windtree Therapeutics (NASDAQ:WINT) Eliminates $15 Million Contingent Liability To Deerfield Management Company
Via ACCESSWIRE
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Windtree Therapeutics (NASDAQ: WINT) Eliminates $15 Million Contingent Liability To Deerfield Management Company
Windtree Therapeutics (NASDAQ: WINT) announced an agreement with affiliates of biopharma investor Deerfield Management Company to fully retire a $15 million contingent liability associated with... 
Via Benzinga
Week in Review: Lee’s Pharma Signs $138 Million Agreement For China Rights To Heart Failure Therapy
Lee’s Pharma acquired China rights to a heart failure therapy from Windtree Therapeutics. Meanwhile, AstraZeneca signed an investment cooperation agreement with the Taizhou National Medical High-tech... 
Via Talk Markets
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback